anipharmaceuticals.com (ANIP): Narxning prognoz qilingan daromadga nisbati
ANI Pharmaceuticals (ANIP) aktivlarini himoya qilish FDA litsenziyalari va raqobatni cheklaydigan shaxsiy ishlab chiqarish zavodlariga asoslangan. GURU.Markets platformasida kutilayotgan P/S qiymatini tahlil qilib, joriy parametr 0.70 ekanligini qayd etamiz. Bu kamyob dori vositalari va murakkab generiklarni chiqarish strategiyasining samaradorligini tasdiqlaydi. Biznes barqarorligi sintezning qat'iy ekologik nazorati va suv resurslaridan barqaror foydalanish bilan yanada to'ldirilgan.
ANI Pharmaceuticals Corp (ANIP) moliyaviy va bozor koʻrsatkichlari kesimi
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- birja kapitallashuvi ma'lumotlari:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- kompaniyaning jami qarzi va likvidligi ko'rsatkichlari:
Qarzning xususiy kapitalga nisbati ANI Pharmaceuticals|ANIP - Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ANI Pharmaceuticals|ANIP - Jamlangan qarz majburiyatlari|Balans kapitallashuviga qarzlar ANI Pharmaceuticals Corp|ANIP - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzi ANI Pharmaceuticals|Tezkor likvidlik anipharmaceuticals.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
ANIP - Sof daromad|Prognoz qilingan kelajakdagi foyda ANI Pharmaceuticals|ANIP - P/E multiplikatori|Forvard P/E multiplikatori ANI Pharma|ANIP - Narx-foyda va o‘sish multiplikatori|EV/EBITDA multiplikatori ANI Pharmaceuticals Corp|ANIP - Foizlar, soliqlar va eskirishdan oldingi foyda|So'nggi 12 oy davomida bir aksiya uchun sof foyda ANI Pharmaceuticals|ANIP - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi anipharmaceuticals.com|ANIP - Joriy yil uchun bitta aksiya uchun sof foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi ANI Pharmaceuticals
- realizatsiya hajmi va tushum ko'rsatkichlari:
Kompaniyaning jamlanma tahlili:ANI Pharmaceuticals, Inc. ANIP
Forward P/S koeffitsiyenti ANI Pharmaceuticals (ANIP) kompaniyasining bozor qiymatini kutilayotgan daromadga nisbatan baholaydi, bu esa investorlarga bozor shovqinlarini filtrlash va aktiv uchun har qanday haqiqiy haddan tashqari to'lovni aniqlash imkonini beradi. ANI Pharmaceuticals formulalarining patent himoyasini hisobga olgan holda, forward P/S koeffitsiyentidagi o'zgarishlar biznesning tartibga soluvchi to'siqlarni barqaror pul oqimiga aylantirish qobiliyatini aks ettiradi va investitsiya qilingan kapitalning uzoq muddatli barqarorligini belgilaydi.
ANI Pharmaceuticals raqobatchilari
Forvard P/S multiplikatori HLN (Haleon)|Forvard P/S multiplikatori Kenvue Inc KVUE|VRNA - Narxning prognoz qilingan daromadga nisbati|MENS (Jyong Bio) - Kapitalizatsiyaning prognoz qilingan daromadga nisbati|LGND: Forvard P/S multiplikatori|AMRX - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|Forvard narx/daromad multiplikatori PRGO|ALVO: Sotuvga nisbatan forvard narx|Narxning prognoz qilingan daromadga nisbati Liquidia Technologies (LQDA)|GLPG: Kelajakdagi narxning daromadga nisbati|Forvard P/S multiplikatori MNKD (MannKind Corporation)|Sotuvga nisbatan forvard narx AMPH|Pacira BioSciences, Inc. - Forvard P/S multiplikatori|SPRY - Forvard P/S multiplikatori|Theravance (TBPH) - Narxning prognoz qilingan daromadga nisbati|Aquestive Corp - Sotuvga nisbatan forvard narx|Narxning prognoz qilingan daromadga nisbati scPharmaceuticals, Inc.|Forvard narx/daromad multiplikatori Tectonic (TECX)|Forvard P/S multiplikatori TNXP|Forvard P/S multiplikatori sxtchina.com (SXTC)|Forvard P/S multiplikatori EPRX (Eupraxia Pharmaceuticals Inc.)|BHST - Forvard narx/daromad multiplikatori|eXoZymes Inc - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Oramed Pharmaceuticals|ENTX (enterabio.com) - Forvard narx/daromad multiplikatori|MindWalk Holdings, Inc. (HYFT) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori ABVC|CPIX (Cumberland Corp) - Narxning kutilayotgan daromadga nisbati|Forvard P/S multiplikatori QNTM|Kapitalizatsiyaning kutilayotgan sotuvga nisbati fibrogen.com|Forvard P/S multiplikatori TELO (Telomir Pharmaceuticals, Inc.)|RANI - Forvard narx/daromad multiplikatori|Synergy CHC Corporation - Forvard P/S multiplikatori|RLYB - Forvard P/S multiplikatori|lexariabioscience.com (LEXX) - Narxning prognoz qilingan daromadga nisbati|PULM (pulmatrix.com) - Narxning prognoz qilingan daromadga nisbati|Narxning prognoz qilingan daromadga nisbati Pheton Holdings Limited|Aptorum (APM) - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|Forvard P/S multiplikatori LYRA|Forvard P/S multiplikatori Impact BioMedical, Inc. (IBO)|Narxning prognoz qilingan daromadga nisbati TNF Pharmaceuticals, Inc. TNFA|YCBD: Kapitalizatsiyaning prognoz qilingan daromadga nisbati|PainReform - Forvard P/S multiplikatori|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Altamira Therapeutics CYTO|Lipella (LIPO) - Narxning prognoz qilingan daromadga nisbati|Kelajakdagi narxning daromadga nisbati OPTN (OptiNose Corp)|Narxning prognoz qilingan daromadga nisbati Pieris Pharmaceuticals|procapsgroup.com - Kelajakdagi narxning daromadga nisbati|Forvard P/S multiplikatori PTPI|QLI (Qilian International Holding Group) - Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori SLRN (ACELYRIN, Inc.)|Forvard P/S multiplikatori TFF Pharmaceuticals, Inc TFFP
